BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/7/2022 10:23:38 AM | Browse: 762 | Download: 1712
Publication Name World Journal of Critical Care Medicine
Manuscript ID 73238
Country United States
ISSN 2220-3141(online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Critical Care Medicine
Manuscript Type Minireviews
Article Title Medicinal nicotine in COVID-19 acute respiratory distress syndrome, the new corticosteroid
Manuscript Source Unsolicited Manuscript
All Author List Farrukh Ahmad
ORCID
Author(s) ORCID Number
Farrukh Ahmad http://orcid.org/0000-0003-0004-441X
Funding Agency and Grant Number
Corresponding Author Farrukh Ahmad, MD, Staff Physician, Department of Internal Medicine, Saint Vincent Hospital, 123, Summer Street, Worcester, MA 01608, United States. farrukh2.ahmad@stvincenthospital.com
Key Words COVID-19; Acute respiratory distress syndrome; Medicinal nicotine; Cholinergic anti-inflammatory pathway; Corticosteroid
Core Tip Cholinergic anti-inflammatory pathway is novel pathway of the inflammatory reflex. Activation of this pathway can suppress maladaptive inflammatory response seen in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). Nicotine is a potent activator of this pathway and may offer benefits in the management of COVID-19 ARDS, via immune suppressive effects similar to dexamethasone.
Publish Date 2022-07-07 10:23
Citation Ahmad F. Medicinal nicotine in COVID-19 acute respiratory distress syndrome, the new corticosteroid. World J Crit Care Med 2022; 11(4): 228-235
URL https://www.wjgnet.com/2220-3141/full/v11/i4/228.htm
DOI https://dx.doi.org/10.5492/wjccm.v11.i4.228
Full Article (PDF) WJCCM-11-228.pdf
Full Article (Word) WJCCM-11-228.docx